UK Biotech

UK bank launches £2.5B plan to fund innovation, with a special place for its long-ailing biotech scene

Can a government-owned bank loaded with cash help trigger a biotech boom in the UK?

We’ll find out.

The British Business Bank has just unveiled a £2.5 billion scheme to invest in “innovative” companies in the UK, and they have a special focus on drug discovery and development.

The BBB is transferring £400 million over to the newly created British Patient Capital to get things going. And they’re starting with a small, £9 million investment in the Dementia Discovery Fund, which is backing life sciences companies in the field. Another £30 million goes to Draper Esprit’s £115 million capital raise.

The idea here is that the government can inspire investments totaling three times their £2.5 billion investment. 

The UK’s Golden Triangle is home to some of the world’s best known scientists, and has a major backer with AstraZeneca and GSK based in the country. But there’s also a strong underlying belief that the country lacks the kind of experienced execs and financial support for the hub to break out of its limited boundaries.


Image: London. SHUTTERSTOCK

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->